An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Acronyms LY03004SAD
- Sponsors Luye Pharma Group
- 08 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2014 New trial record